Solubility-Driven Optimisation of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate
Tools
Tools
Press, Neil, Taylor, Roger, Fullerton, Joe, Tranter, Pamela, Mccarthy, Clive, Keller, Thomas, Arnold, Nicola, Brown, Lyndon, Cheung, Robert, Christie, Julie, Denholm, Alastair, Haberthuer, Sandra, Keenan, Mark, Hatto, Julia, Mercer, Mark, Oakman, Helen, Sahri, Helene, Trifilieff, Alexandre, Tuffnell, Andrew, Tweed, Morris, Wagner, Beatrix, Beer, David, Tyler, John and Fozard, John R. (2012) Solubility-Driven Optimisation of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate. Journal of medicinal chemistry, 55 (17). pp. 7472-7479. ISSN 0022-2623
Abstract
The solubility-driven optimisation of a series of 1,7-napthyridine phosphodiesterase 4 inhibitors is described. Directed structural changes resulted in increased aqueous solubility, enabling superior pharmacokinetic properties, with retention of PDE4 inhibition. A range of potent and orally bioavailable compounds with good in vivo efficacy in animal models of inflammation and reduced emetic potential compared to previously described drugs were synthesised. Compound 2d was taken forward as a clinical candidate for the treatment of COPD.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Additional Information: | All compounds previously disclosed in patent applications or oral presentations |
| Keywords: | Phosphodiesterase-4; Asthma; COPD; Anti- inflammatory, solubility-driven optimisation |
| Related URLs: | |
| Date Deposited: | 13 Oct 2015 13:15 |
| Last Modified: | 13 Oct 2015 13:15 |
| URI: | https://oak.novartis.com/id/eprint/5109 |